Barclays set a €100.00 ($119.05) price objective on Bayer (FRA:BAYN) in a research note issued to investors on Tuesday morning. The brokerage currently has a sell rating on the healthcare company’s stock.
BAYN has been the subject of a number of other reports. J P Morgan Chase & Co reissued a buy rating on shares of Bayer in a research report on Tuesday, August 29th. set a €105.00 ($125.00) price target on Bayer and gave the company a neutral rating in a research report on Tuesday, August 29th. Berenberg Bank set a €121.00 ($144.05) price target on Bayer and gave the company a neutral rating in a research report on Tuesday, August 29th. Jefferies Group set a €137.00 ($163.10) price target on Bayer and gave the company a buy rating in a research report on Tuesday, August 29th. Finally, Baader Bank set a €120.00 ($142.86) price target on Bayer and gave the company a neutral rating in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the company. Bayer presently has a consensus rating of Buy and a consensus target price of €122.19 ($145.46).
Shares of Bayer (FRA:BAYN) opened at €106.05 ($126.25) on Tuesday. Bayer has a 52-week low of €93.07 ($110.80) and a 52-week high of €123.82 ($147.40).
ILLEGAL ACTIVITY NOTICE: “Bayer (BAYN) Given a €100.00 Price Target by Barclays Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/13/bayer-bayn-given-a-100-00-price-target-by-barclays-analysts.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.